Self harm: assessment, management and preventing recurrence
In development [GID-NG10148] Expected publication date: 18 May 2022
Search results
2112 results
-
-
Gout: diagnosis and management
In development [GID-NG10151] Expected publication date: 13 June 2022
-
Rehabilitation after traumatic injury
In development [GID-NG10105] Expected publication date: 23 November 2021
-
Chronic pain: assessment and management
In development [GID-NG10069] Expected publication date: TBC
-
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management
In development [GID-NG10149] Expected publication date: 08 June 2022
-
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s
In development [GID-NG10098] Expected publication date: TBC
-
Heart valve disease presenting in adults: investigation and management
In development [GID-NG10122] Expected publication date: 08 September 2021
-
Atrial fibrillation: management
In development [GID-NG10100] Expected publication date: 12 March 2021
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management
In development [GID-NG10185] Expected publication date: TBC
-
Chronic kidney disease: assessment and management (update)
In development [GID-NG10118] Expected publication date: 30 June 2021
-
Inducing labour (update)
In development [GID-NG10082] Expected publication date: 14 October 2021
-
Caesarean section (update)
In development [GID-NG10081] Expected publication date: 31 March 2021
-
Melanoma: assessment and management
In development [GID-NG10155] Expected publication date: 25 May 2022
-
Subarachnoid haemorrhage due to ruptured aneurysms
In development [GID-NG10097] Expected publication date: 21 July 2021
-
Hypertension in adults: diagnosis and management (update)
In development [GID-NG10177] Expected publication date: 19 April 2023
-
Endo-SPONGE for treating low rectal anastomotic leakage (MT461)
In development [GID-MT539] Expected publication date: TBC
-
Peezy Midstream for urine collection (MT446)
In development [GID-MT538] Expected publication date: TBC
-
The MAGEC system for spinal lengthening in children with scoliosis
In development [GID-MT544] Expected publication date: 15 September 2020
-
Alpha Stim AID (MT477)
In development [GID-MT542] Expected publication date: 08 March 2021
-
V.A.C. VERAFLO Therapy System for acute infected or chronic wounds that are failing to heal (MT471)
In development [GID-MT543] Expected publication date: 27 January 2020
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)
In development [GID-MT531] Expected publication date: TBC
-
Synergo for non-muscle-invasive bladder cancer
In development [GID-MT553] Expected publication date: TBC
-
MT582 AnaConDa
In development [GID-MT556] Expected publication date: 23 February 2022
-
Sleepio for adults with difficulty sleeping (MT443)
In development [GID-MT552] Expected publication date: 03 August 2021
-
Prontosan for acute and chronic wounds
In development [GID-MT551] Expected publication date: 05 October 2021
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: 22 March 2022
-
DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)
In development [GID-MT550] Expected publication date: 04 October 2021
-
Leukomed Sorbact for preventing surgical site infection (MT496)
In development [GID-MT541] Expected publication date: 03 February 2021
-
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)
In development [GID-MT548] Expected publication date: 04 May 2021
-
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation
In development [GID-MT554] Expected publication date: 06 January 2022
-
MT507 Plus Sutures for preventing surgical site infection (MIB204)
In development [GID-MT558] Expected publication date: 09 November 2021
-
3C Patch System for treating diabetic foot ulcers (MT539)
In development [GID-MT559] Expected publication date: 19 January 2022
-
Danis Stent for acute oesophageal variceal bleeds (MT450)
In development [GID-MT537] Expected publication date: 25 May 2021
-
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children
-
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
-
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
-
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency
-
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
-
Migalastat for treating Fabry disease (HST4)
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
-
Eliglustat for treating type 1 Gaucher disease (HST5)
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
-
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
-
Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa in adults and children
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged
-
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder